	US 11,753,640 B2
	Oligonucleotides for modulating Tau expression
Peter Hagedorn, Hørsholm (DK); Anja Mølhart Høg, Hillerød (DK); Richard E. Olson, Cambridge, MA (US); and Marianne L. Jensen, Køge (DK)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Dec. 31, 2020, as Appl. No. 17/139,161.
Application 17/139,161 is a continuation of application No. PCT/EP2019/067799, filed on Jul. 3, 2019.
Claims priority of provisional application 62/726,005, filed on Aug. 31, 2018.
Claims priority of provisional application 62/693,851, filed on Jul. 3, 2018.
Prior Publication US 2021/0123054 A1, Apr. 29, 2021
Int. Cl. C12N 15/113 (2010.01)

CPC C12N 15/113 (2013.01) [C12Y 301/26004 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/32 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/341 (2013.01); C12N 2310/351 (2013.01); C12N 2330/30 (2013.01)]

8 Claims

1. An antisense oligonucleotide of formula CAACaccttttaattcATTA (CMP ID NO: 53_1; SEQ ID NO: 53) or a pharmaceutically acceptable salt thereof, wherein capital letters are beta-D-oxy LNA nucleosides, lowercase letters are DNA nucleosides, all LNA C nucleobases are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages.